Zacks Investment Research Lowers Curis (NASDAQ:CRIS) to Hold

Curis (NASDAQ:CRISGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

A number of other research firms also recently issued reports on CRIS. StockNews.com assumed coverage on shares of Curis in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Raymond James downgraded shares of Curis from an “outperform” rating to a “market perform” rating and set a $15.00 price target on the stock. in a research note on Monday, April 4th. Cantor Fitzgerald reduced their price target on shares of Curis from $12.00 to $4.00 in a research note on Tuesday, April 5th. Finally, B. Riley reduced their price target on shares of Curis from $22.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, April 5th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.85.

NASDAQ:CRIS traded up $0.17 on Tuesday, hitting $1.02. The stock had a trading volume of 1,518,413 shares, compared to its average volume of 2,361,573. The stock has a market cap of $93.48 million, a price-to-earnings ratio of -1.79 and a beta of 3.15. The company has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $3.57. Curis has a 1-year low of $0.83 and a 1-year high of $17.40.

Curis (NASDAQ:CRISGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Curis had a negative net margin of 490.80% and a negative return on equity of 50.59%. During the same quarter last year, the business earned ($0.11) earnings per share. Analysts forecast that Curis will post -0.63 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in CRIS. Maverick Capital Ltd. increased its stake in Curis by 284.7% during the 3rd quarter. Maverick Capital Ltd. now owns 7,577,489 shares of the biotechnology company’s stock worth $59,332,000 after buying an additional 5,607,753 shares during the period. M28 Capital Management LP purchased a new stake in Curis during the 4th quarter worth approximately $12,418,000. Millennium Management LLC increased its stake in Curis by 2,477.8% during the 4th quarter. Millennium Management LLC now owns 2,005,163 shares of the biotechnology company’s stock worth $9,545,000 after buying an additional 1,927,376 shares during the period. Polar Capital Holdings Plc increased its position in shares of Curis by 60.7% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,214,700 shares of the biotechnology company’s stock valued at $25,171,000 after purchasing an additional 1,214,700 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in shares of Curis by 34.1% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 4,054,920 shares of the biotechnology company’s stock valued at $19,302,000 after purchasing an additional 1,031,914 shares during the last quarter. 78.15% of the stock is currently owned by hedge funds and other institutional investors.

About Curis (Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Recommended Stories

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.